Furthermore, in the context of potential pharmaceutical intervention, treatment of COPAdeficient THP-1 cells with small-molecule STING inhibitor H-151 was able to markedly reduce baseline STAT1 phosphorylation (Fig. 2d) and type I IFN-mediated gene transcription (Fig. 2e), thus indicating a possible targeted treatment for COPA syndrome patients. The gene discussed is STING1; the disease is autoimmune interstitial lung disease-arthritis syndrome.